Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHA: 688266)
China flag China · Delayed Price · Currency is CNY
62.50
+0.06 (0.10%)
Nov 19, 2024, 3:00 PM CST

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Company Description

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. researches and develops, manufactures, and sells medicines in the People's Republic of China.

It offers donafenib tablets; recombinant human thrombin for topincal use; jacktinib tablets; and recombinant human thyroid-stimulating hormone for injection; obeticholic acid magnesium tablets; ZG19018 tablets; ZG005 powder for injection; and alkotinib capsules for the treatment of liver cancer, non-small cell lung cancer, small cell lung cancer, colorectal cancer, thyroid cancer, and neuroendocrine cancer, as well as multiple therapeutic areas, such as bleeding, hepatobiliary diseases, and autoimmune diseases.

The company was founded in 2009 and is based in Kunshan, the People's Republic of China.

Suzhou Zelgen Biopharmaceuticals Co.,Ltd.
Country China
Founded 2009
Industry Biotechnology
Sector Healthcare
Employees 867
CEO Zelin Sheng

Contact Details

Address:
No. 209, Chenfeng Road
Kunshan, 215300
China
Phone 86 512 5701 8310
Website zelgen.com

Stock Details

Ticker Symbol 688266
Exchange Shanghai Stock Exchange
Fiscal Year January - December
Reporting Currency CNY
ISIN Number CNE100003RP1
SIC Code 2836

Key Executives

Name Position
Zelin Sheng Chairman of the Board and GM
Gang Huang Chief Financial Officer and Deputy GM
Zeqi Sheng Chief Scientific Officer
Huiping Lu Executive Vice President and Director
Jisheng Wu Director and Deputy GM
Binhua Lv Deputy General Manager and Director
Qingping Gao Deputy GM and Board Secretary